Clinical and Immunological Therapy for Solid Tumors

Dear Colleagues,

In recent years, immunotherapies for solid tumors have generated spectacular outcomes for cancer patients in clinics. Adoptive cell therapies (ACT), including using autologous tumor-infiltrating lymphocyte (TILs), TCR T-cells (TCR-engineered T cell), chimeric antigen receptor (CAR) T cells, tumor vaccines and checkpoint blockade, have emerged as the most effective treatments for solid tumors. The current challenge for solid cancer immunotherapies is that although some patients have benefited from these treatments, many cancers will still have variable responses. The purpose of this Special Issue is to understand the treatment advantages and disadvantages in order to provide exciting opportunities for effective anticancer immunotherapies for solid tumors. This Special Issue welcomes reviews, as well as original research articles, which should be submitted by 30 June 2024.

Dr. Biaoru Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• TCR T cells, TIL
• CAR T cells and tumor vaccines
• immunotherapy and adoptive cell transfer
• personalized immunotherapy and genomics analysis
• T-cell homing which includes T-cell rolling, adhesion, extravasation, and chemotaxis into the solid tumor